Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2026
Respiratory biologics utilization, prescription predictors, and outcomes in patients with asthma and comorbid overweight or obesityDinah Foer, Diane L Seger, Julie Fiskio, et al.
Respiratory Medicine|September 11, 2024
Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristicsTanawin Nopsopon, Alyson Brown, Georg Hahn, et al.
Frontiers in Allergy|October 17, 2025
Machine learning-derived genetic risk scores identify IL21 as a predictor of response to omalizumab and dupilumab in asthmaAyobami Akenroye, Chengyue Zhang, Tanawin Nopsopon, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 27, 2016
Identifying Allergic Drug Reactions Through Placebo-Controlled Graded ChallengesMelissa Iammatteo, Denisa Ferastraoaru, Rebecca Koransky, et al.
The Journal of Allergy and Clinical Immunology|June 30, 2022
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysisAyobami Akenroye, Grace Lassiter, John W Jackson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 22, 2021
Metformin Use and Risk of Asthma Exacerbation Among Asthma Patients with Glycemic DysfunctionTianshi David Wu, Ashraf Fawzy, Ayobami Akenroye, et al.
Allergy|January 2, 2024
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumabTanawin Nopsopon, Nora A Barrett, Wanda Phipatanakul, et al.
The Journal of Allergy and Clinical Immunology|December 20, 2022
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysisTanawin Nopsopon, Grace Lassiter, Ming-Li Chen, et al.
Pageof 3